KR20050024272A - 신경 퇴행성 질환의 치료방법 - Google Patents

신경 퇴행성 질환의 치료방법 Download PDF

Info

Publication number
KR20050024272A
KR20050024272A KR1020040070116A KR20040070116A KR20050024272A KR 20050024272 A KR20050024272 A KR 20050024272A KR 1020040070116 A KR1020040070116 A KR 1020040070116A KR 20040070116 A KR20040070116 A KR 20040070116A KR 20050024272 A KR20050024272 A KR 20050024272A
Authority
KR
South Korea
Prior art keywords
phenyl
substituted
disease
furyl
neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020040070116A
Other languages
English (en)
Korean (ko)
Inventor
후웬-메이
류호웅-치
루다-유
텡체-밍
쿠오생-추
리팡-유
Original Assignee
칼스배드 테크놀로지 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼스배드 테크놀로지 인코퍼레이티드 filed Critical 칼스배드 테크놀로지 인코퍼레이티드
Publication of KR20050024272A publication Critical patent/KR20050024272A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020040070116A 2003-09-03 2004-09-02 신경 퇴행성 질환의 치료방법 Ceased KR20050024272A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/653,859 US20040077702A1 (en) 2001-09-14 2003-09-03 Treatment of nuerodegenerative diseases
US10/653,859 2003-09-03

Publications (1)

Publication Number Publication Date
KR20050024272A true KR20050024272A (ko) 2005-03-10

Family

ID=34136658

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020040070116A Ceased KR20050024272A (ko) 2003-09-03 2004-09-02 신경 퇴행성 질환의 치료방법

Country Status (8)

Country Link
US (1) US20040077702A1 (https=)
EP (1) EP1512400B1 (https=)
JP (1) JP2005075834A (https=)
KR (1) KR20050024272A (https=)
CN (1) CN1626077A (https=)
AT (1) ATE460161T1 (https=)
DE (1) DE602004025885D1 (https=)
TW (1) TW200510329A (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
US20080200557A1 (en) * 2004-07-07 2008-08-21 Caritas St. Elizabeth Hospital Of Boston, Inc. Method for Inhibiting Lipid Peroxidation
US20080252028A1 (en) * 2007-04-16 2008-10-16 Ming-Tai Huang Shock absorbing device for toy stroller
WO2008136772A1 (en) * 2007-05-02 2008-11-13 Agency For Science, Technology And Research Method of monitoring retinopathy
US20140163082A1 (en) 2011-05-06 2014-06-12 King Khalid Eye Specialist Hospital Pyrazolyl compounds for use in reversing reactive gliosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105149A (en) * 1870-07-05 Egbert l
US4355A (en) * 1846-01-15 Beehive
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US7115661B1 (en) * 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
US5760230A (en) * 1996-10-11 1998-06-02 Bayer Aktiengesellschaft 4, 4'-bridged bis-2, 4-diaminoquinazolines
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
GB9920566D0 (en) * 1999-08-31 1999-11-03 Univ London Screen for axon viability
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
DE60201921T2 (de) * 2001-01-24 2005-10-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Kondensierte Pyrazolverbindungen
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
US7049334B2 (en) * 2001-09-14 2006-05-23 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier

Also Published As

Publication number Publication date
DE602004025885D1 (de) 2010-04-22
US20040077702A1 (en) 2004-04-22
JP2005075834A (ja) 2005-03-24
TW200510329A (en) 2005-03-16
EP1512400A1 (en) 2005-03-09
CN1626077A (zh) 2005-06-15
EP1512400B1 (en) 2010-03-10
ATE460161T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
KR100997174B1 (ko) 혈관 신생 억제제
Hikino et al. Antiinflammatory principles of Caesalpinia sappan wood and of Haematoxylon campechianum wood1
KR20230121808A (ko) 약제학적 활성 화합물로서 칸나비노이드 유도체 및이의 제조 방법
US9687469B2 (en) Agent containing flavonoid derivatives for treating cancer and inflammation
JPH04503360A (ja) カプサイシン様応答のための活性の可変スペクトルを有する化合物の新規種類、それらの組成物および用途
KR20110044947A (ko) 과잉활성 면역계 치료를 위한 사이클로리그난의 용도
JP6517833B2 (ja) 神経変性疾患の処置に有用なウィザノライド
KR20040099300A (ko) 온혈 동물의 면역, 소염, 항암 및 ｄｎａ 수복 과정을향상시키기 위한 식물 종의 수용성 추출물의 생체 활성성분을 단리 및 정제하고 그의 구조를 확인하는 방법
KR20060050772A (ko) 신생혈관 형성 방지 방법
KR20050024272A (ko) 신경 퇴행성 질환의 치료방법
EP0792148B1 (en) Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity
CZ292302B6 (cs) Léčivo pro ošetřování amyloidosy, anthracyklin, způsob jeho přípravy a farmaceutický prostředek s jeho obsahem
CN100398544C (zh) 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
CN101730565B (zh) 取代膦酸酯及其用于减少淀粉样聚集物的用途
AU2002241521B2 (en) Anti-inflammatory compounds derived from pseudopterogorgia elisabethae
JP6305422B2 (ja) 老化関連疾患を克服するためにｓｈｃ−１／ｐ６６を抑制する方法
KR100889515B1 (ko) 학습능력 및 기억능력의 증진 방법, 및 기억상실의 치료방법
CN113214097A (zh) 治疗阿尔茨海默病的化合物
AU2002241521A1 (en) Anti-inflammatory compounds derived from pseudopterogorgia elisabethae
CN105712982B (zh) 二氢-β-沉香呋喃型倍半萜类化合物、其制法和用途
KR20030095197A (ko) 패혈증의 치료 방법
CN117586214B (zh) 乌药烷型倍半萜二聚体及其制备方法和用途
JP2988937B2 (ja) 海洋源由来の新規の抗腫瘍性及び抗ウイルス性組成物
EP0042348A1 (fr) Dérivés de l'olivacine et leur application thérapeutique
RU2799454C2 (ru) Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20040902

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090814

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20040902

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110412

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110920

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110412

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I